tbuckley/cabot-search huggingface dataset:
Abstract 1411: A novel molecular approach for head and neck cancer radiosensitization
Authors: Shunsuke Miyamoto, Hui Wang, Taku Yamashita, Daqing Li, Bert W. O'Malley
Journal: Cancer Research (2010)

Abstract Purpose: Current combined external beam radiation therapy (XRT) and chemotherapy have demonstrated as an effective treatment against advanced head and neck cancers. However, combined modality treatments often result in unacceptable levels of toxicity to the patients. It has been well-known that enhanced DNA double strand break (DSB) repairing by Mre11, Rad50 and Nbs1 (MRN) complex is one of the most important mechanisms for developing radioresistance in the tumor cells. The present study investigates if the use of targeted Rad50 disruption could sensitize the tumor cells to XRT for the treatment of human head and neck squamous cell carcinoma (HNSCC). Our goal is to establish a most effective treatment strategy while minimizing XRT morbidity for the HNSCC. Method: Two human HNSCC tumor cell lines, JHU012 and JHU022, and an animal model with human HNSCC were used in this study. A dominant-negative recombinant adenoviral vector containing mutant Rad50 (Ad-Rad50) was constructed. The tumors were treated with Ad-Rad50, replication-defective virus (DL312), or untreated as mock control and a 2-Gy XRT. Cell viability and tumor volume were evaluated to analyze anti-tumor activity of different treatment groups. Neutral comet assay was performed for evaluating DNA DSB damage. Apoptosis in tumor cells was studied by using immunohistochemistry. Result: Our study demonstrates that the transgene expression of mutant Rad50 significantly interrupts the DNA DSB repairing and increases DNA damage in the tumor cells. Increased levels of tumor cell apoptosis were found associated with combined Ad-Rad50 and XRT treatment group. The combined Ad-Rad50 and XRT treatment shows the best anti-tumor result as compared to other groups both in vitro and in vivo. Conclusion: The present study suggests that Ad-Rad50 gene transfer effectively interrupts DNA DSB repairing and results in radiosensitizing in the HNSCC tumor cells treated with XRT. This strategy can be further investigated in the clinic for the treatment of advanced human head and neck cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1411.
Abstract 4070: β-arrestin-2 mediated regulation of plasminogen activator inhibitor Type 1.
Authors: Philip M. Sobolesky, Tanyau Zhou, Arielle Gorstein, Julie A. Woolworth, Omar Moussa
Journal: Cancer Research (2013)

Abstract Several studies described the elevated levels of plasminogen activated Inhibitor-1 (PAI-1) protein in malignant tissues and indicated the potential use as a therapeutic target. In bladder cancer, higher levels of PAI-1 were found in tumor tissues compared to normal tissues. Urinary levels of PAI-1 protein in combination with other markers resulted in higher sensitivity and specificity in detecting bladder cancer. In human kidney mesangial cells, the thromboxane A2 (TP) receptor agonist stimulation increased PAI-1 mRNA and protein. Our lab indicated that TP receptor is highly expressed in bladder cancer tissues and inversely correlated with patients` survival. We also indicated the TPβ isoform can induce malignant transformation in immortalized non-transformed urothelial cells. Our published data indicated that U46619 dependent stimulation of cell migration is β-arrestin-2 dependent. The purpose of the current study is to investigate the mechanism whereby TP stimulation regulates PAI-1 expression. The protein levels of PAI-1 were found to be increased in bladder cancer cells following stimulation with TP agonist (U46619). Tetracycline inducible shRNA knock-down of β-arrestin-2 resulted in a significant reduction of PAI-1 protein, but not mRNA in bladder cancer cells and also resulted in a significant reduction of trans-well cell migration and invasion. Our data suggest that the agonist mediated increase in PAI-1 is regulated at the post-transcriptional level. The role of β-arrestin-2 KD on agonist dependent stimulation remains to be determined. Citation Format: Philip M. Sobolesky, Tanyau Zhou, Arielle Gorstein, Julie A. Woolworth, Omar Moussa. β-arrestin-2 mediated regulation of plasminogen activator inhibitor Type 1. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4070. doi:10.1158/1538-7445.AM2013-4070
THU0133 Intra-articular methotrexate: Clinical and power doppler ultrasonography study of synovitis in medium seized joints of rheumatoid arthritis patients
Authors: M. Mortada, A. Solyman
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The effects of intra_articular methotrexate (I/A MTX)in knee synovitis in rheumatoid arthritis have been previously evaluated (1). I/A MTX has not been studied in other joints. Ultrasonography (US) has been little studied in I/A MTX. <h3>Objectives</h3> To test the efficacy of I/A MTX in rheumatoid arthritis patients with persistent synovitis resistant to systemic methotrexate and other disease modifying antirheumatic drugs (DMARDS) in medium sized joints (ankle, wrist and elbow). <h3>Methods</h3> 10 mg of methotrexate was injected intra_articularly in 42 joints (14 wrists, 12 elbows and 16 ankles) in 36 consecutive RA patients with mono/oligo arthritis resistant to systemic DMARDS including methotrexate and other joints in clinical remission. The injection was every week for 8 weeks. Clinical evaluation includes visual analogue scale (VAS), tenderness and swelling was graded on a semiquantitative scale from 0 to 3. Evaluation was done before the 1st injection (W0), 1 week after the 4th injection (W5), 1 week after the last injection (W8) and 3 months later (W20). On the same days Power Doppler US was done. Synovial thickness and the intra_articular power Doppler signal was graded on a semiquantitative scale from 0 to 3 during the US examination. <h3>Results</h3> There was significant reduction in VAS (mean value± SD) between W0 (9±0.5) and W5 (1±1) p&lt;0.001, between W0 (9±0.5) and W8 (0±1) p&lt;0.001 and between W0 and W20 (2.5±0.5) p&lt;0.01. Tenderness and swelling reduced significantly between W0 (2±1) and W5 (1±1) p&lt;0.001, between W0 and W8 (0±1) p&lt;0.05 and between W0 and W20 (0±1) p&lt;0.001. Gray US and power Doppler US showed that synovial thickness and intra_articular power signals was reduced significantly between (W0 &amp; W5) and (W0 &amp; W8). While there was insignificant increase in synovial thickness between W8 and W20. There was significant increase in Power Doppler signals between W8 and W20 p&lt;0.05. Safety: Only 2 participants reported multiple oral ulcerations during the study. <h3>Conclusions</h3> Repeated I/A MTX resulted in a decrease in degree of synovitis of medium seized joints in RA patients both clinically and by power Doppler US. While the clinical effects and the decrease in synovial thickness by gray US continue after 3 months, power Doppler signals tends to increase after 3 months. To the best of our knowledge this the first study to detect the effect of I/A MTX by power Doppler US in medium seized joints. <h3>References</h3> Iagnocco A, Cerioni A., Coari G. Ossandon A, Masciangelo R., Valesini G. Intra-articular methotrexate in the treatment of rheumatoid arthritis and psoriatic arthritis: a clinical and sonographic study. Clin Rheumatol. 2006 Mar; 25(2):159-63 <h3>Disclosure of Interest</h3> None Declared
QUANTIFICATION OF CHANGES IN 3-D REGURGITANT FRACTION AND LEFT VENTRICULAR STROKE VOLUME IMMEDIATELY AFTER SURGICAL MITRAL VALVE REPAIR FOR DEGENERATIVE MITRAL VALVE DISEASE USING AUTOMATED REAL-TIME VOLUME COLOR FLOW DOPPLER TRANS-ESOPHAGEAL ECHOCARDIOGRAPHY
Authors: Shizhen Liu, Naveen Rajpurohit, William Whitley, John Meisinger, Venkateshwar Polsani, Hassan Sayegh, Xiao Zhou, Helene Houle, Randoph Martin, Federico Milla, Mani Vannan
Journal: Journal of the American College of Cardiology (2016)
Abstract 4041: Identification of GNG7 as an epigenetically silenced gene in head and neck cancer by gene expression profiling
Authors: Semra Demokan, Alice Y. Chuang, Xiaofei Chang, Tanbir Khan, Ian M. Smith, Kavita M. Pattani, Santanu Dasgupta, Shahnaz Begum, Zubair Khan, Nanette J. Liegeois, William H. Westra, David Sidransky, Wayne Koch, Joseph A. Califano
Journal: Cancer Research (2012)

Abstract Silencing of tumor suppressor genes plays a vital role in head and neck carcinogenesis. Aberrant hypermethylation in the promoter region of some known or putative tumor suppressor genes occurs frequently during the development of various cancers including head and neck squamous cell carcinoma (HNSCC). In this study we used an expanded mRNA expression profiling approach followed by microarray expression analysis to identify epigenetically inactivated genes in HNSCC. Two HNSCC cell lines were treated with 5-aza-2′-deoxycytidine followed by microarray analysis to identify epigenetically silenced genes in HNSCC. 1960, 614, and 427 genes were upregulated in HNSCC cell lines JHU-012, JHU-011 and the combination of both cell lines, respectively. HNSCC tumor and normal mucosal samples were used for gene profiling by a 47K mRNA gene expression array and we found, 7140 genes were downregulated in HNSCC tumors compared to normal mucosa as determined by microarray analysis and were integrated with cell line data. Integrative analysis defined 126 candidate genes, of which only seven genes showed differentially methylation in tumors and no methylation in normal mucosa after bisulfite sequencing. After validation by QMSP, one gene, GNG7, was confirmed as being highly methylated in tumors and unmethylated in normal mucosal and salivary rinse samples demonstrating cancer-specific methylation in HNSCC tissues. TXNIP and TUSC2 were partially methylated in tumors and normal salivary rinses but unmethylated in normal mucosa. We concluded GNG7 as a highly specific promoter methylated gene associated with HNSCC. In addition, TXNIP and TUSC2 are also potential biomarkers for HNSCC. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4041. doi:1538-7445.AM2012-4041
Why Strategy Matters Now
Authors: Michael E. Porter, Thomas H. Lee
Journal: New England Journal of Medicine (2015)

Interview with Dr. Thomas Lee on a strategic approach to value for health care organizations seeking to compete in the current market. (07:33)Download In a changing environment, health care organizations need to rethink the meaning of strategy and make the choices necessary to distinguish themselves in meeting customers' needs. Those choices revolve around six key questions, beginning with "What is our goal?"
Cancer Out of the Closet: Support Emerges Over Two Decades
Authors: J. A. Steele
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article Cancer Out of the Closet: Support Emerges Over Two Decades Get access Julie A. Steele Julie A. Steele Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 16, 21 August 1991, Pages 1130–1131, https://doi.org/10.1093/jnci/83.16.1130 Published: 21 August 1991
RT-16 * LARGE OCULOMOTOR NERVE SCHWANNOMA - RARE ENTITY. A CASE REPORT
Authors: P. Lachi, M. Irrakula, F. Syed, M. Uppin, D. Joseph, A. Syed, D. Nair, V. Krishna, S. Pamidighantam, K. Naidu
Journal: Neuro-Oncology (2014)

Schwannomas commonly arise from peripheral nerves. Intracranial schwannomas are comparatively rare and are seen commonly as vestibular tumors. Oculomotor nerve schwannomas are extremely rare tumors, these are usually symptomatic. A 29 year aged male presented with diplopia and blurring of vision in left eye and found to have a extra axial lesion at left cavernous sinus involving the left oculomotor nerve schwannoma. The excised tumor showed classic morphology of a schwannoma. Post operatively patient developed complete oculomotor nerve palsy. The tumor recurred after 2 years. It was re-excised followed by radiotherapy.
Abstract 2372: Predictive markers in patients with non-small cell lung cancer with pemetrexed treatment.
Authors: Hiun S. Chae, Yoon Ho Ko, Eun Kyoung Jeon, Sook Hee Hong, Jeong-Oh Kim, Seung Joon Kim, Kyo Young Lee, Young Kyoon Kim, HoonKyo Kim, Seok young Park, In Sook Woo, Jin Hyoung Kang
Journal: Cancer Research (2013)

Abstract Background: This study is desiged to evaluate biomarkers that are correlated with the efficacy of pemetrexed in patients with non-small-cell lung cancer (NSCLC). Methods: Patients with stage III or IV NSCLC who received pemetrexed monotherapy after failure of one or more chemotherapy regimen between January 2003 and August 2011 were included. Polymorphism of reduced folate carrier gene (SLC19A, rs1051298), 5,10-methylenetetrahydroflate reductase (MTHFR, rs1801133) and thymidylate synthase (TS, rs45445694, rs16430) gene were analyzed by PCR and direct sequencing method using peripheral blood. Results: Total 123 patients were included. The median age was 61 years (range 35-82). Fifty eight (47.2%) patients were female. Predominant histology was adenocarcinoma (92.7%). Metastatic diseases were 114 (80.5%) patients. Patients received one or more lines of systemic therapy before pemetrexed therapy, one line in 53 (43.1%) patients, two in 51(41.5%), three in 14 (11.02%), and four in 4 (3.3%). Median 4 cycles of chemotherapy were given (range 1-44). Response rate was 22.7% (CR, n=2, PR, n=26) and stable disease was detected in 54 patients (43.9%). Median follow up duration was 28.7months (range 4.07-84.33months). Median progression free survival (PFS) was 4.2 months (95% CI: 2.9-5.6) and median overall survival (OS) was 18.9 months (95% CI: 13.3-24.6). Clinical factors like, sex, histology of tumor (adenocarcinoma vs, nonadenocarcinoma), differentiation, smoking status and EGFR mutation status (active mutation vs. other mutation vs. wild type) did not have any significant difference on response and PFS. Only polymorphisms of TS promoter enhancer region (TSER) were related with PFS. 2R/2R repeat in the TSER (2R/2R vs 2R/3R, 3R/3R 1.0m vs 4.3m, p&amp;lt;0.01) and CC homozygote variant in second repeat of the 3R allele (CC vs GC, GG 2.8m vs 5.0m, p=0.04) had poor PFS. All polymorphism did not have effect on response rate and overall survival. Conclusions: This study suggests that polymorphisms of TSER associated PFS in pemetrexed treatment. Further prospective studies will be needed to validate these polymorphism as a useful biomarker of pemetrexed treatment in NSCLC patients. Citation Format: Hiun S. Chae, Yoon Ho Ko, Eun Kyoung Jeon, Sook Hee Hong, Jeong-Oh Kim, Seung Joon Kim, Kyo Young Lee, Young Kyoon Kim, HoonKyo Kim, Seok young Park, In Sook Woo, Jin Hyoung Kang. Predictive markers in patients with non-small cell lung cancer with pemetrexed treatment. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 2372. doi:10.1158/1538-7445.AM2013-2372
Abstract 4284: Combined magnetic resonance and fluorescence-protein imaging to simultaneously assess the anti-tumor and anti-angiogenesis efficacy of selenium
Authors: Arup Bhattacharya, Steve G. Turowski, Ivan Dominguez San Martin, Ashwani Rajput, Youcef M. Rustum, Robert M. Hoffman, Mukund Seshadri
Journal: Cancer Research (2011)

Abstract In this report, we determined the feasibility to combine fluorescent protein imaging (FPI) and magnetic resonance imaging (MRI) to demonstrate the efficacy of selenium on tumor progression and angiogenesis of colon cancer in an orthotopic model. GEO human colon carcinoma cells expressing green fluorescent protein (GFP), were implanted orthotopically into the colon of athymic nude mice. Beginning 5 days post implantation, whole body FPI was performed to monitor tumor growth in vivo. Upon visualization of tumor growth by FPI, animals were randomly assigned to either a control group or a treatment group. Treatment consisted of daily oral administration of the organoselenium compound, methyselenocysteine (MSC; 0.2 mg/day × 5 weeks). Longitudinal monitoring of tumor growth was performed using FPI and MRI. In addition, dynamic contrast-enhanced MRI was performed to examine the change in tumor blood volume following treatment. Changes in tumor vascularity visualized by imaging were correlated with immunohistochemical determination of microvessel density. Both FPI and MRI allowed non-invasive visualization of the longitudinal growth of orthotopic colon tumors. While T1- and T2-weighted MRI provided adequate contrast and volumetric assessment of GEO tumor growth, GFP imaging allowed for high-throughput visualization of tumor progression. Selenium treatment resulted in a significant reduction in blood volume and microvessel density of GEO tumors. A significant inhibition of tumor growth was also observed in selenium-treated animals compared to untreated control animals. Together, these results highlight the usefulness of multimodal imaging approaches to demonstrate antitumor and anti-angiogenesis efficacy and the potential of selenium treatment of colon cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4284. doi:10.1158/1538-7445.AM2011-4284
Case 25-1981
Authors: Richard C. Cabot, Robert E. Scully, James J. Galdabini, Betty U. McNeely, Frank C. Wheelock, James J. Galdabini
Journal: New England Journal of Medicine (1981)

Presentation of CaseA 40-year-old woman was admitted to the hospital because of recurrent gastrointestinal bleeding.Ten years earlier she underwent surgical repair of a hiatus hernia at another hospital. Within 24 hours she was returned to the operating room because of an unknown complication. During the following year a stitch was removed from an incision site. At about the same time she began to complain of intermittent pain in the left shoulder that was aggravated by coughing. She was otherwise well until two months before admission, when she had a febrile illness accompanied by arthralgia and myalgia. The fever . . .
Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
Authors: Wei Wang, Jorge E. Cortes, Guilin Tang, Joseph D. Khoury, Sa Wang, Carlos E. Bueso-Ramos, Joseph A. DiGiuseppe, Zi Chen, Hagop M. Kantarjian, L. Jeffrey Medeiros, Shimin Hu
Journal: Blood (2016)
OC-022 Development And Outcome Of Intestinal Failure In Crohn’s Disease: 3 Decades Of Experience From A National Referral Centre
Authors: E Nixon, P Allan, S Sidhu, A Abraham, A Teubner, G Carlson, S Lal
Journal: Gut (2014)

<h3>Introduction</h3> Intestinal Failure (IF) is a rare complication of Crohn’s disease (CD) which carries significant morbidity, for which there is a relative paucity of data. We describe a large series of patients with CD and IF and evaluate factors associated with IF development. <h3>Methods</h3> This was a retrospective study from a prospectively maintained database of patients referred to a national IF centre. Patients with CD were identified if on home parenteral nutrition (PN) for at least 12 months in the period between 1980–2011, and case notes were reviewed. Severe IF was defined as onset of IF within 15 years of CD diagnosis. Comparison of frequencies was performed using the Chi-squared test. Multivariate logistic regression models were used to identify independent associated factors after univariate analysis. <h3>Results</h3> 78 patients were identified. The median time from CD diagnosis to commencing PN was 120 (12–552) months. Median time from CD diagnosis to first surgery was 36 (0–312) months. Patients underwent a median of 3 (1–7) small bowel (SB) resections prior to commencing PN, and the median remnant SB length was 130 (40–375) cm. Patients underwent a total of 312 operations but data were unavailable for 3 of these. The primary indication for the first surgery was stricturing (61.5%), followed by penetrating (23.1%) and inflammatory (15.4%) disease. Operative complications were higher in patients undergoing emergency (37/85; 43.5%) vs. elective (53/224; 23.7%) procedures (p = 0.001) and in surgeries performed outside (87/255; 34.1%) vs. within (3/54; 5.6%) the IFU (p &lt; 0.0001)). 234 subsequent operations were undertaken after the first, but indication data were missing in 7 operations; operative complications were the primary indication for surgical intervention in (76/227) 33.5% of cases after the first surgery. In multivariate analysis, severe IF was associated with surgical complications (p = 0.003), higher number of SB resections (p = 0.005) and earlier age of CD diagnosis (p = 0.005). 25/78 (32.1%) patients achieved nutritional autonomy during a median follow-up of 36 (12–376) months after commencing PN. There were 68 documented catheter infections (0.42 infections/1000 catheter days) in this patient cohort. 9 patients died during follow-up as a result of liver disease (n = 3), complex CD/overwhelming sepsis (n = 2) or other causes (n = 4). <h3>Conclusion</h3> Recurrent surgeries with operative complications are significant factors leading to severe IF. These are important considerations in guiding therapeutic decisions in CD, given the morbidity associated with chronic IF. <h3>Disclosure of Interest</h3> None Declared.
Corrigendum re: “Suppression of Heat Shock Protein 27 Using OGX-427 Induces Endoplasmic Reticulum Stress and Potentiates Heat Shock Protein 90 Inhibitors to Delay Castrate-resistant Prostate Cancer” [Eur Urol 2014;66:145–55]
Authors: François Lamoureux, Christian Thomas, Min-Jean Yin, Ladan Fazli, Amina Zoubeidi, Martin E Gleave
Journal: European Urology (2016)